Scholarlink

<p>Few studies have thoroughly evaluated the symptom burden and quality of life (QOL) among patients diagnosed with hematologic malignancies who underwent chimeric antigen receptor T-cell (CAR-T) therapy. In total, 97 eligible patients completed the Functional Assessment of Cancer Therapy generic scale (FACT-G) at week 4 after CAR-T cell infusion. We used the Common Terminology Criteria Adverse Events (CTCAE) to measure symptom burden of CAR-T patients during the same period. We studied factors associated with QOL using liner regression analysis. During the period of hospitalization after CAR-T treatment, the prevalence of self-reported symptoms among CAR-T patients was highest for fatigue (89.7%), followed by sleep disorders (79.4%) and decreased appetite (66.0%). And the mean score of FACT-G was 69.06 (SD = 13.88). Liner regression analysis showed that decreased appetite (<i>β</i> = -0.30, 95% CI = -7.48 to -1.83, <i>P</i> = 0.002), fatigue (<i>β</i> = -0.28, 95% CI = -7.23– -1.69, <i>P</i> = 0.002), nausea (<i>β</i> = -0.26, 95% CI = -10.50 to -2.16, <i>P</i> = 0.003) and a history of hematopoietic stem cell transplantation (HSCT) (<i>β</i> = -0.21, 95% CI = -13.38– -1.56, <i>P</i> = 0.014) were associated with poorer quality of life. The symptom burden experienced by patients undergoing CAR-T treatment is substantial during their hospitalization, and it is closely associated with a diminished quality of life. It is imperative for clinical medical staff to be attentive to the symptom burden of CAR-T patients and to enhance the effectiveness of symptom management interventions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月22日

查看全文
  • Hongyuan Dai,
  • Shuya Xu,
  • Zengxiang Wang,
  • Zhenyu Li,
  • Jiang Cao,
  • Tingyu Hu,
  • Fang Zhou

摘要

Few studies have thoroughly evaluated the symptom burden and quality of life (QOL) among patients diagnosed with hematologic malignancies who underwent chimeric antigen receptor T-cell (CAR-T) therapy. In total, 97 eligible patients completed the Functional Assessment of Cancer Therapy generic scale (FACT-G) at week 4 after CAR-T cell infusion. We used the Common Terminology Criteria Adverse Events (CTCAE) to measure symptom burden of CAR-T patients during the same period. We studied factors associated with QOL using liner regression analysis. During the period of hospitalization after CAR-T treatment, the prevalence of self-reported symptoms among CAR-T patients was highest for fatigue (89.7%), followed by sleep disorders (79.4%) and decreased appetite (66.0%). And the mean score of FACT-G was 69.06 (SD = 13.88). Liner regression analysis showed that decreased appetite (β = -0.30, 95% CI = -7.48 to -1.83, P = 0.002), fatigue (β = -0.28, 95% CI = -7.23– -1.69, P = 0.002), nausea (β = -0.26, 95% CI = -10.50 to -2.16, P = 0.003) and a history of hematopoietic stem cell transplantation (HSCT) (β = -0.21, 95% CI = -13.38– -1.56, P = 0.014) were associated with poorer quality of life. The symptom burden experienced by patients undergoing CAR-T treatment is substantial during their hospitalization, and it is closely associated with a diminished quality of life. It is imperative for clinical medical staff to be attentive to the symptom burden of CAR-T patients and to enhance the effectiveness of symptom management interventions.